Table 3.
Multivariate logistic regression analyses of selected biomarkers for predicting higher risk of AKI.
| Range, pg/ml | OR (95% CI) | p | Adjusteda OR (95% CI) | Adjusted p | |
|---|---|---|---|---|---|
| GDF15 | Continuous | 5.59 (3–13.9) | 0 | 6.64 (3–19.4) | 0.0001 |
| Q1 | (203, 522) | 1 | Ref | 1 | Ref |
| Q2 | (522, 1.37e+03) | 4.36 (1.04–23.21) | 0.0567 | 5.82 (1.19–37.35) | 0.0401 |
| Q3 | (1.37e+03, 2.28e+03) | 7.33 (1.73–39.9) | 0.0109 | 8.01 (1.6–53.17) | 0.0171 |
| Q4 | (2.28e+03, 4.75e+03) | 101.33 (13.76–2231) | 1e−04 | 161.36 (16.89–4295.26) | 1e−04 |
| IL1RL1 | Continuous | 2.86 (2–6.07) | 0.0018 | 3.59 (2–8.4) | 0.0007 |
| Q1 | (3.93e+03, 9.19e+03) | 1 | Ref | 1 | Ref |
| Q2 | (9.19e+03, 1.63e+04) | 1.44 (0.39–5.59) | 0.5844 | 2.21 (0.48–11.42) | 0.3169 |
| Q3 | (1.63e+04, 2.73e+04) | 2.98 (0.81–11.88) | 0.1073 | 5.8 (1.25–32.5) | 0.032 |
| Q4 | (2.73e+04, 6.27e+04) | 12.28 (2.85–69.26) | 0.0017 | 25.56 (4.86–185.8) | 4e−04 |
| UPAR | Continuous | 1.96 (1–3.46) | 0.0115 | 2.15 (1–4.21) | 0.0146 |
| Q1 | (1.95e+03, 3.69e+03) | 1 | Ref | 1 | Ref |
| Q2 | (3.69e+03, 5.26e+03) | 1.4 (0.39–5.19) | 0.6051 | 2.22 (0.48–11.53) | 0.3184 |
| Q3 | (5.26e+03, 6.26e+03) | 2.36 (0.65–9.05) | 0.1972 | 4.61 (1.01–24.84) | 0.0581 |
| Q4 | (6.26e+03, 1.02e+04) | 5.14 (1.36–22.07) | 0.0197 | 6.87 (1.57–36.43) | 0.015 |
OR, odds ratio; Q1, the first quartile; Q2, the second quartile; Q3, the third quartile; Q4, the fourth quartile; RRT, renal replacement therapy; GDF-15, growth/differentiation factor-15; IL1RL1, interleukin 1 receptor like 1; UPAR, urokinase plasminogen activator.
a
Adjusted for age, sex, diabetes, hypertension, previous heart disease, eGFR, and hemoglobin.